Anti-obesity Prescription Drugs Market Research Report by Drug Class (Bupropion and Naltrexone, Liraglutide, Lorcaserin, Orlistat, and Phentermine and Topiramate), by Age Group (Adult and Pediatric), by Distribution Channel - United States Forecast to 2025 - Cumulative Impact of COVID-19
The United States Anti-obesity Prescription Drugs Market is projected to grow with a significant CAGR in the forecast period. Economic development and substantial infrastructure development have constituted regional revenue generation. Further, the patterns associated with domestic production, import and export, and consumption have helped market participants to analyze and capitalize on potential opportunities. Besides, the qualitative and quantitative parameters provided in the report with detailed analysis highlights the driving and restraining factors of the United States Anti-obesity Prescription Drugs Market.
Market Segmentation & Coverage: This research report categorizes the Anti-obesity Prescription Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Drug Class, the Anti-obesity Prescription Drugs Market studied across Bupropion and Naltrexone, Liraglutide, Lorcaserin, Orlistat, and Phentermine and Topiramate.
Based on Age Group, the Anti-obesity Prescription Drugs Market studied across Adult and Pediatric.
Based on Distribution Channel, the Anti-obesity Prescription Drugs Market studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
Company Usability Profiles: The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the United States Anti-obesity Prescription Drugs Market including Arena Pharmaceuticals, Inc, F Hoffmann La Roche Ltd, GlaxoSmithKline, Novo Nordisk A/s, and Orexigen Therapeutics, Inc.
FPNV Positioning Matrix: The FPNV Positioning Matrix evaluates and categorizes the vendors in the Anti-obesity Prescription Drugs Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Competitive Strategic Window: The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.
Cumulative Impact of COVID-19: COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.
The report provides insights on the following pointers: 1. Market Penetration: Provides comprehensive information on the market offered by the key players 2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments
The report answers questions such as: 1. What is the market size and forecast of the United States Anti-obesity Prescription Drugs Market? 2. What are the inhibiting factors and impact of COVID-19 shaping the United States Anti-obesity Prescription Drugs Market during the forecast period? 3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Anti-obesity Prescription Drugs Market? 4. What is the competitive strategic window for opportunities in the United States Anti-obesity Prescription Drugs Market? 5. What are the technology trends and regulatory frameworks in the United States Anti-obesity Prescription Drugs Market? 6. What are the modes and strategic moves considered suitable for entering the United States Anti-obesity Prescription Drugs Market?
Our reports have been used by over 10K customers, including:
Anti-obesity Prescription Drugs Market Research Report by Drug Class (Bupropion and Naltrexone, Liraglutide, Lorcaserin, Orlistat, and Phentermine and Topiramate), by Age Group (Adult and Pediatric), by Distribution Channel - Global Forecast to 2025 - Cumulative Impact of COVID-19 The Global Anti-obesity Prescription...
Obesity - Pipeline Review, H2 2020 Summary latest Pharmaceutical and Healthcare disease pipeline guide Obesity - Pipeline Review, H2 2020, provides an overview of the Obesity (Metabolic Disorders) pipeline landscape. Obesity is defined as having an excessive amount of body fat. Obesity increases...
211 pages •
By Asia Market Information & Development Company
• Sep 2020
China’s demand for Anti-Obesity Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption...
73 pages •
By Asia Market Information & Development Company
• Sep 2020
This study focuses on China’s Anti-Obesity Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is...
PharmaVitae explores Boehringer Ingelheim’s prescription pharmaceutical performance and outlook over 2019–29. Snapshot Overview – Boehringer Ingelheim will see near-term growth, but will see long-term revenue declines because of fewer NMEs in its late-stage pipeline compared to its peers. Key themes –  Upcoming...
PharmaVitae explores Teva’s prescription pharmaceutical performance and outlook over 2019–29. Snapshot Overview – Teva will look to build on the launches of Austedo and Ajovy to counter the erosion of Copaxone, the litigation risk around opioids in the US, and the company’s high debt burden. Key themes –  Launch...
PharmaVitae explores Biogen’s prescription pharmaceutical performance and outlook over 2019–29. Snapshot Overview – Biogen’s prescription pharmaceutical business will see stable performance over the medium term. Key themes –  Biogen’s flagship MS portfolio – Tecfidera, Avonex, Plegridy, and Tysabri – remains...
Blood Glucose Meters - Medical Devices Pipeline Assessment, 2020 Summary Medical Devices sector report, “Blood Glucose Meters - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Blood Glucose Meters pipeline products with comparative analysis of the products...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.